Integrated HIV Prevention and HCV Care for PWID

NAActive, not recruitingINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HIV PreventionHCVOpioid UseIntravenous Drug Usage
Interventions
BEHAVIORAL

ARTAS Adapted Patient Navigation

Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.

BEHAVIORAL

Adherence Counseling

Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.

Trial Locations (3)

10032

Columbia University Irving Medical Center, New York

33136

Miami, Miami

Unknown

Montreal, Montreal

All Listed Sponsors
collaborator

Université de Montréal

OTHER

collaborator

University of Miami

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Université de Sherbrooke

OTHER

collaborator

Simon Fraser University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

lead

Columbia University

OTHER